Butriptyline

Summary

Butriptyline (CHEMBL2110816) is an approved small molecule (ATC N06AA15); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AA15
• Indications: 1 condition
• Chemistry: 293.4 Da · C21H27N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110816
Name	Butriptyline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	21772
ATC	N06AA15
Molecular formula	C21H27N
Molecular weight	293.4
InChIKey	ALELTFCQZDXAMQ-UHFFFAOYSA-N

SMILES: CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)CN(C)C

IUPAC name: N,N,2-trimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propan-1-amine

Also known as: Butriptilina, Butriptyline, Evadene, Evadyne, SID170466439, BUTRIPTYLINE, butriptyline

Parent form; salt/anhydrous children: CHEMBL2106170

Patent coverage: 1,082 distinct patent families (4,533 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,507 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M1, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Alpha-1A adrenergic receptor, Histamine H1 receptor, D(3) dopamine receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	7.82	AC50	15	nM	CHEMBL_ACT_25212118
CHRM1	6.64	AC50	230	nM	CHEMBL_ACT_25135058
CHRM3	5.85	AC50	1400	nM	CHEMBL_ACT_25136320
DRD3	5.77	AC50	1700	nM	CHEMBL_ACT_25193147
KCNH2	5.68	AC50	2100	nM	CHEMBL_ACT_25117286
HTR2C	5.52	AC50	3000	nM	CHEMBL_ACT_25131430
ADRA2B	5.3	AC50	5000	nM	CHEMBL_ACT_25143322
ADRA2C	5.16	AC50	6900	nM	CHEMBL_ACT_25147485

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).